IMNM Stock Analysis: Immunome | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.131m USD | 12M Return: 173.1% | US45257U1088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.4M
Warnings
Tailwinds
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Immunome, Inc. (NASDAQ: IMNM) is a U.S.-based biotechnology company focused on discovering, developing, and commercializing antibody-drug conjugates (ADCs) and other oncology therapeutics. Its lead clinical asset, Varegacestat, is a gamma secretase inhibitor currently in Phase 3 trials for desmoid tumors, while IM-1021, a ROR1-targeted ADC, is in Phase 1 development. The company is also advancing several preclinical candidates, including a FAP-targeted radioligand therapy (IM-3050) and additional solid tumor ADCs (IM-1617, IM-1340, and IM-1335).
Founded in 2006 and headquartered in Bothell, Washington, Immunome went public in October 2020 and operates within the Health Care / Biotechnology GICS sub-industry. As a clinical-stage biotech, its business model centers on advancing a pipeline of targeted cancer therapies through trials toward potential commercialization, with ADCs representing a class of oncology drugs that combine the targeting specificity of antibodies with potent cytotoxic agents.
- Varegacestat Phase 3 data readout in desmoid tumors
- ADC pipeline expansion with IM-1021 advancing through trials
- Cash runway supports clinical development through key milestones
| Net Income: -254.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA 24.08 > 1.0 |
| NWC/Revenue: 7.24k% < 20% (prev 2.02k%; Δ 5.22k% < -1%) |
| CFO/TA -0.37 > 3% & CFO -208.8m > Net Income -254.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.3m) vs 12m ago 30.18% < -2% |
| Gross Margin: 57.43% > 18% (prev 79.25%; Δ -21.82% > 0.5%) |
| Asset Turnover: 1.61% > 50% (prev 4.25%; Δ -2.64% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.89 (Total Current Assets 538.4m - Total Current Liabilities 35.7m) / Total Assets 565.4m |
| B: -1.51 (Retained Earnings -855.1m / Total Assets 565.4m) |
| C: -0.59 (EBIT TTM -254.3m / Avg Total Assets 430.8m) |
| D: 13.03 (Book Value of Equity 525.1m / Total Liabilities 40.3m) |
| Altman-Z'' = 10.62 = AAA |
As of September 06, 2026, the stock is trading at USD 26.76 with a total of 562,126 shares traded. Over the past week, the price has changed by -2.94%, over one month by +6.78%, over three months by +35.98% and over the past year by +173.06%.
Current recommended Stop Loss: 25.10 (which is 6.2% or 1.2 ATR below the current price).
Immunome has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy IMNM.
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 36.3 | 35.7% |
P/S = 791.7903
P/B = 6.2479
Revenue TTM = 6.94m USD
EBIT TTM = -254.3m USD
EBITDA TTM = -251.2m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 8.28m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.69m
Net Debt = -511.7m USD (calculated: Debt 8.28m - CCE 520.0m)
Enterprise Value = 2.62b USD (3.13b + Debt 8.28m - CCE 520.0m)
Interest Coverage Ratio = unknown (Ebit TTM -254.3m / Interest Expense TTM 0.0)
EV/FCF = -11.96x (Enterprise Value 2.62b / FCF TTM -219.1m)
FCF Yield = -8.36% (FCF TTM -219.1m / Enterprise Value 2.62b)
FCF Margin = -3.16k% (FCF TTM -219.1m / Revenue TTM 6.94m)
Net Margin = -3.66k% (Net Income TTM -254.3m / Revenue TTM 6.94m)
Gross Margin = 57.43% ((Revenue TTM 6.94m - Cost of Revenue TTM 2.96m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.63 (Enterprise Value 2.62b / Total Assets 565.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 8.28m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -200.9m (EBIT -254.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.08 (Total Current Assets 538.4m / Total Current Liabilities 35.7m)
Debt / Equity = 0.02 (Debt 8.28m / totalStockholderEquity, last quarter 525.1m)
Debt / EBITDA = 2.04 (negative EBITDA) (Net Debt -511.7m / EBITDA -251.2m)
Debt / FCF = 2.34 (negative FCF - burning cash) (Net Debt -511.7m / FCF TTM -219.1m)
Total Stockholder Equity = 503.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.03% (Net Income -254.3m / Total Assets 565.4m)
RoE = -50.56% (Net Income TTM -254.3m / Total Stockholder Equity 503.0m)
RoCE = -48.02% (EBIT -254.3m / Capital Employed (Total Assets 565.4m - Current Liab 35.7m))
RoIC = -37.96% (negative operating profit) (NOPAT -200.9m / Invested Capital 529.3m)
WACC = 9.81% (E(3.13b)/V(3.14b) * Re(9.84%) + D(8.28m)/V(3.14b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.45 | Cagr: 190.2%
[DCF] Fair Price = unknown (Cash Flow -219.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.12 | # QB: -1
Revenue Correlation: -42.34 | Revenue CAGR: -15.06% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.50 | Chg30d=+0.00% | Revisions=+75% | Analysts=13
EPS current Year (2026-12-31): EPS=-2.31 | Chg30d=-8.75% | Revisions=+67% | GrowthEPS=+4.9% | GrowthRev=-95.2%
EPS next Year (2027-12-31): EPS=-2.48 | Chg30d=-16.96% | Revisions=-25% | GrowthEPS=-7.3% | GrowthRev=+16567.7%
[Analyst] Revisions Ratio: +72% (up=20, down=2)